Business Description
Quoin Pharmaceuticals Ltd
NAICS : 541715
SIC : 2834
ISIN : US74907L4095
Share Class Description:
QNRX: ADRTotal Employee Number:
6Description
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.56 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 78 | |||||
3-Year EPS without NRI Growth Rate | 79.5 | |||||
3-Year FCF Growth Rate | 79.4 | |||||
3-Year Book Growth Rate | -75.8 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 48.76 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 33.21 | |||||
9-Day RSI | 41.09 | |||||
14-Day RSI | 43.08 | |||||
3-1 Month Momentum % | -32.22 | |||||
6-1 Month Momentum % | -56.57 | |||||
12-1 Month Momentum % | -48.14 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.87 | |||||
Quick Ratio | 2.87 | |||||
Cash Ratio | 2.63 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -399.8 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -291.37 | |||||
ROA % | -131.96 | |||||
ROIC % | -2777.35 | |||||
3-Year ROIIC % | 2254.17 | |||||
ROCE % | -226.66 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 0.93 | |||||
Price-to-Tangible-Book | 0.97 | |||||
EV-to-EBIT | 0.33 | |||||
EV-to-EBITDA | 0.33 | |||||
EV-to-Forward-Revenue | 0.28 | |||||
EV-to-FCF | 0.36 | |||||
| Price-to-Net-Current-Asset-Value | 0.97 | |||||
| Price-to-Net-Cash | 1.15 | |||||
Earnings Yield (Greenblatt) % | 303.03 | |||||
FCF Yield % | -189.29 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:QNRX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Quoin Pharmaceuticals Ltd Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -16.5 | ||
| Beta | 1.1003 | ||
| 3-Year Sharpe Ratio | -0.61 | ||
| 3-Year Sortino Ratio | -0.84 | ||
| Volatility % | 138.18 | ||
| 14-Day RSI | 43.08 | ||
| 14-Day ATR ($) | 0.463059 | ||
| 20-Day SMA ($) | 4.429 | ||
| 12-1 Month Momentum % | -48.14 | ||
| 52-Week Range ($) | 3.25 - 41.8 | ||
| Shares Outstanding (Mil) | 2.01 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Quoin Pharmaceuticals Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Quoin Pharmaceuticals Ltd Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-06 | In 113 days | ||
| General meeting for 2026 | 2026-08-21 12:00 | In 37 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | In 22 days | ||
| First quarter earnings results for 2026 | 2026-05-07 | 6.43 (+0.78%) | ||
| Annual report for 2025 | 2026-03-26 | 9.27 (-7.58%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-26 | 9.27 (-7.58%) | ||
| Third quarter earnings results for 2025 | 2025-11-06 | 9.65 (-1.53%) | ||
| General meeting for 2025 | 2025-08-21 12:00 | 7.06 (-3.29%) | ||
| Second quarter earnings results for 2025 | 2025-08-07 | 7.37 (+3.22%) | ||
| First quarter earnings results for 2025 | 2025-05-13 | 6.12 (+0.66%) |
Show
Entries
Quoin Pharmaceuticals Ltd Frequently Asked Questions
What is Quoin Pharmaceuticals Ltd(QNRX)'s stock price today?
The current price of QNRX is $4.15. The 52 week high of QNRX is $41.80 and 52 week low is $3.25.
When is next earnings date of Quoin Pharmaceuticals Ltd(QNRX)?
The next earnings date of Quoin Pharmaceuticals Ltd(QNRX) is 2026-08-07 Est..
Does Quoin Pharmaceuticals Ltd(QNRX) pay dividends? If so, how much?
Quoin Pharmaceuticals Ltd(QNRX) does not pay dividend.
Guru Commentaries on NAS:QNRX
No articles.
Press Release
| Subject | Date | ||
|---|---|---|---|
| Thinking about buying stock in Weibo Corp, Spotify, NiSource, General Electric, or Quoin Pharmaceuticals? | 2022-01-31 |
Articles on Quoin Pharmaceuticals Ltd
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers